AU2016321884B2 - Improvement of expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein - Google Patents

Improvement of expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein Download PDF

Info

Publication number
AU2016321884B2
AU2016321884B2 AU2016321884A AU2016321884A AU2016321884B2 AU 2016321884 B2 AU2016321884 B2 AU 2016321884B2 AU 2016321884 A AU2016321884 A AU 2016321884A AU 2016321884 A AU2016321884 A AU 2016321884A AU 2016321884 B2 AU2016321884 B2 AU 2016321884B2
Authority
AU
Australia
Prior art keywords
rap
sequence
seq
particular embodiments
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016321884A
Other languages
English (en)
Other versions
AU2016321884A1 (en
Inventor
Eckart Bartnik
Paul Habermann
Bernd Janocha
Volker Jeske
Joachim SAAS
Isabell Schoettle
Ursula STILLGER
Judith STOMMES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionet Pharma GmbH
Original Assignee
Bionet Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionet Pharma GmbH filed Critical Bionet Pharma GmbH
Publication of AU2016321884A1 publication Critical patent/AU2016321884A1/en
Application granted granted Critical
Publication of AU2016321884B2 publication Critical patent/AU2016321884B2/en
Priority to AU2021202110A priority Critical patent/AU2021202110A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2016321884A 2015-09-18 2016-09-16 Improvement of expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein Ceased AU2016321884B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021202110A AU2021202110A1 (en) 2015-09-18 2021-04-06 Improvement of expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15306457.1 2015-09-18
EP15306457 2015-09-18
EP15306458 2015-09-18
EP15306458.9 2015-09-18
EP15306950 2015-12-07
EP15306950.5 2015-12-07
PCT/EP2016/071947 WO2017046314A2 (en) 2015-09-18 2016-09-16 Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021202110A Division AU2021202110A1 (en) 2015-09-18 2021-04-06 Improvement of expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein

Publications (2)

Publication Number Publication Date
AU2016321884A1 AU2016321884A1 (en) 2018-04-12
AU2016321884B2 true AU2016321884B2 (en) 2021-01-07

Family

ID=57223637

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016321884A Ceased AU2016321884B2 (en) 2015-09-18 2016-09-16 Improvement of expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein
AU2021202110A Abandoned AU2021202110A1 (en) 2015-09-18 2021-04-06 Improvement of expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021202110A Abandoned AU2021202110A1 (en) 2015-09-18 2021-04-06 Improvement of expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein

Country Status (8)

Country Link
US (2) US10660852B2 (enExample)
EP (1) EP3350204A2 (enExample)
JP (1) JP6976254B2 (enExample)
CN (1) CN108602866A (enExample)
AU (2) AU2016321884B2 (enExample)
CA (1) CA2998665A1 (enExample)
TW (1) TW201726712A (enExample)
WO (1) WO2017046314A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210219569A1 (en) * 2018-03-16 2021-07-22 Eco-Geo Bio-Technology Company Limited Use and composition of buffer formulation with multiple ph values and protein digestion enhancer
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
FR3092339B1 (fr) * 2019-02-05 2024-04-12 Michelin & Cie Cellule, notamment levure, resistante au phloroglucinol
CN113024675A (zh) * 2020-12-29 2021-06-25 山东第一医科大学(山东省医学科学院) 一种hb-nc4重组蛋白及其制备方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1191099A1 (en) * 1999-06-30 2002-03-27 Takeda Chemical Industries, Ltd. Novel polypeptide and dna thereof
EP1604693A1 (en) * 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
WO2008040556A1 (en) * 2006-10-06 2008-04-10 Scil Technology Gmbh Dried reconstituted vesicle formation for pharmaceutical application
WO2011113604A1 (en) * 2010-03-17 2011-09-22 Universität Regensburg Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein
WO2011134979A2 (en) * 2010-04-27 2011-11-03 Scil Technology Gmbh Stable mia/cd-rap formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1005153B (el) * 1989-08-29 2006-03-13 The General Hospital Corporation Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
JP4579378B2 (ja) * 1999-06-30 2010-11-10 武田薬品工業株式会社 新規ポリペプチドおよびそのｄｎａ

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1191099A1 (en) * 1999-06-30 2002-03-27 Takeda Chemical Industries, Ltd. Novel polypeptide and dna thereof
EP1604693A1 (en) * 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
WO2008040556A1 (en) * 2006-10-06 2008-04-10 Scil Technology Gmbh Dried reconstituted vesicle formation for pharmaceutical application
WO2011113604A1 (en) * 2010-03-17 2011-09-22 Universität Regensburg Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein
WO2011134979A2 (en) * 2010-04-27 2011-11-03 Scil Technology Gmbh Stable mia/cd-rap formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLESCH A ET AL, "CLONING OF A NOVEL MALIGNANT MELANOMA-DERIVED GROWTH-REGULATORY PROTEIN, MIA", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (1994-11-01), vol. 54, ISSN 0008-5472, pages 5695 - 5701 *

Also Published As

Publication number Publication date
WO2017046314A2 (en) 2017-03-23
US10660852B2 (en) 2020-05-26
TW201726712A (zh) 2017-08-01
AU2016321884A1 (en) 2018-04-12
CN108602866A (zh) 2018-09-28
US20190046442A1 (en) 2019-02-14
JP2018527030A (ja) 2018-09-20
AU2021202110A1 (en) 2021-05-06
EP3350204A2 (en) 2018-07-25
CA2998665A1 (en) 2017-03-23
WO2017046314A3 (en) 2017-05-26
US20200268663A1 (en) 2020-08-27
JP6976254B2 (ja) 2021-12-08

Similar Documents

Publication Publication Date Title
AU2021202110A1 (en) Improvement of expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein
CN114728078B (zh) 与分子连接的细胞外囊泡及其用途
Fernandes et al. A structure-based proposal for a comprehensive myotoxic mechanism of phospholipase A2-like proteins from viperid snake venoms
AU2016365751B2 (en) Use of C-type natriuretic peptide variants to treat osteoarthritis
US20230193274A1 (en) Extracellular vesicles with stat3-antisense oligonucleotides
JP7682503B2 (ja) コラーゲン結合薬剤組成物およびその使用方法
US20230158100A1 (en) Treatment of panx1 associates diseases
KR20220124196A (ko) 사이클릭 펩티드 수용체 란티오닌 신테타제 c-유사 단백질 (lancl) 및 이의 용도
US20230132093A1 (en) Extracellular vesicle-nlrp3 antagonist
CN102666845B (zh) 磷酸酶和张力蛋白同系物(pten)抑制剂组合物,用途以及方法
WO2014194428A1 (en) Targeted heparan sulfatase compounds
KR20210061388A (ko) 피부학적 질환의 치료제
MX2007011487A (es) Peptidos de factor de crecimiento mecanico y su uso.
US9670250B2 (en) Alpha-helical peptidomimetic inhibitors and methods using same
US12214076B2 (en) Drug delivery vehicles for atherosclerosis nanomedicine
US20240158441A1 (en) Branched peptides for enzymatic assembly and mitochondria drug delivery
WO2015077317A1 (en) Compositions and methods for the purification and production of butyrylcholinesterase
TW202311529A (zh) β-己糖胺酶變體之組合物及其用途
AU2006224334A1 (en) Mecano growth factor peptides and their use
HK40074902A (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
EP4562156A2 (en) Extracellular vesicle-aso constructs targeting cebp/beta
KR101580313B1 (ko) Ｄｎａ 메틸트랜스퍼레이즈 저해제를 유효성분으로 포함하는 ｈｂｖ의 감염에 의한 간 손상 복구용 조성물
WO2011038054A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING Gα PROTEIN SIGNALING

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired